Preclinical evidence of new opioid modulators for the treatment of addiction

Bibliography

• Substance Abuse and Mental Health Services Administration. Results from the 2008. National Survey on Drug Use and Health: National Findings (Office of Applied Studies, NSDUH Series H-36, HHS Publication No. SMA 09-4434). Rockville, MD, 2009
   Google Scholar
• The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) 2009 Annual report on the state of the drugs problem in Europe. European Monitoring Centre for Drugs and Drug Addiction. Luxembourg: Publications Office of the European Union, 2009
   Google Scholar
• Stotts AL, Dodrill CL, Kosten TR. Opioid dependence treatment: options in pharmacotherapy. Expert Opin Pharmacother 2009;10:1-14
   PubMedGoogle Scholar
• Gardner EL. Use of animal models to develop antiaddiction medications. Curr Psychiatry Rep 2008;10:377-84
   PubMedGoogle Scholar
• Tzschentke, TM. Measuring reward with the conditioned place preference (CPP) paradigm: update of the last decade. Addict Biol 2007;12:227-462
   PubMed Web of Science ®Google Scholar
• Bodnar RJ. Endogenous opiates and behavior: 2008. Peptides 2009;30:2432-79
   PubMed Web of Science ®Google Scholar
• Peles E, Kreek MJ, Kellogg S, Adelson M. High methadone dose significantly reduces cocaine use in methadone maintenance treatment (MMT) patients. J Addict Dis 2006;25:43-50
   PubMed Web of Science ®Google Scholar
• Leri F, Zhou Y, Goddard B, Steady-state methadone blocks cocaine seeking and cocaine-induced gene expression alterations in the rat brain. Eur Neuropsychopharmacol 2009;19:238-49
   PubMed Web of Science ®Google Scholar
• Placenza FM, Rajabi H, Stewart J. Effects of chronic buprenorphine treatment on levels of nucleus accumbens glutamate and on the expression of cocaine-induced behavioral sensitization in rats. Psychopharmacology 2008;200:347-55
   PubMed Web of Science ®Google Scholar
• Wolstein J, Gastpar M, Finkbeiner T, A randomized, open-label trial comparing methadone and Levo-Alpha-Acetylmethadol (LAAM) in maintenance treatment of opioid addiction. Pharmacopsychiatry 2009;42:1-8
   PubMed Web of Science ®Google Scholar
• Fishman M. Precipitated withdrawal during maintenance opioid blockade with extended release naltrexone. Addiction 2008;103:1399-401
   PubMed Web of Science ®Google Scholar
• Van Bockstaele EJ, Qian Y, Sterling RC, Page ME. Low dose naltrexone administration in morphine dependent rats attenuates withdrawal-induced norepinephrine efflux in forebrain. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:1048-56
   PubMed Web of Science ®Google Scholar
• Martin TJ, Kim SA, Lyupina Y, Smith JE. Differential involvement of mu-opioid receptors in the rostral versus caudal nucleus accumbens in the reinforcing effects of heroin in rats: evidence from focal injections of beta-funaltrexamine. Psychopharmacology 2002;161:152-9
   PubMed Web of Science ®Google Scholar
• Guo N, Garcia MM, Taylor BK, Blockade of micro-opioid receptors in the medial thalamus inhibits acquisition, but not expression, of morphine-induced conditioned place preference. Neuroscience 2008;151(4):948-54
   PubMed Web of Science ®Google Scholar
• Smith MA, Greene-Naples JL, Lyle MA, The effects of repeated opioid administration on locomotor activity: I. opposing actions of mu and kappa receptors. J Pharmacol Exp Ther 2009;330:468-75
   PubMed Web of Science ®Google Scholar
• Manzanedo C, Aguilar MA, Rodriguez-Arias M, Minarro J. Sensitization to the rewarding effects of morphine depends on dopamine. Neuroreport 2005;16:201-5
   PubMed Web of Science ®Google Scholar
• Kuzmin A, Stenback T, Liljequist S. Memantine enhances the inhibitory effects of naltrexone on ethanol consumption. Eur J Pharmacol 2008;584:352-6
   PubMed Web of Science ®Google Scholar
• Williams KL, Broadbridge CL. Potency of naltrexone to reduce ethanol self-administration in rats is greater for subcutaneous versus intraperitoneal injection. Alcohol 2009;43:119-26
   PubMed Web of Science ®Google Scholar
• Williams KL, Schimmel JS. Effect of naltrexone during extinction of alcohol-reinforced responding and during repeated cue-conditioned reinstatement sessions in a cue exposure style treatment. Alcohol 2008;42:553-63
   PubMed Web of Science ®Google Scholar
• Walker BM, Koob GF. Pharmacological evidence for a motivational role of kappa-opioid systems in ethanol dependence. Neuropsychopharmacology 2008;33:643-52
   PubMed Web of Science ®Google Scholar
• Wee S, Orio L, Ghirmai S, Inhibition of kappa opioid receptors attenuated increased cocaine intake in rats with extended access to cocaine. Psychopharmacology 2009;205:565-75
   PubMed Web of Science ®Google Scholar
• Jayaram-Lindstrom N, Hammarberg A, Beck O, Franck J. Naltrexone for the treatment of amphetamine dependence: a randomized, placebo-controlled trial. Am J Psychiatry 2008;165:1442-8
   PubMed Web of Science ®Google Scholar
• Todtenkopf MS, O'Neill KS, Kriksciukaite K, Route of administration affects the ability of naltrexone to reduce amphetamine-potentiated brain stimulation reward in rats. Addict Biol 2009;14:408-18
   PubMed Web of Science ®Google Scholar
• Haggkvist J, Lindholm S, Franck J. The opioid receptor antagonist naltrexone attenuates reinstatement of amphetamine drug-seeking in the rat. Behav Brain Res 2009a;197:219-24
   PubMed Web of Science ®Google Scholar
• Haggkvist J, Lindholm S, Franck J. The effect of naltrexone on amphetamine-induced conditioned place preference and locomotor behaviour in the rat. Addict Biol 2009b;14:260-9
   PubMed Web of Science ®Google Scholar
• Klein G, Juni A, Arout CA, Acute and chronic heroin dependence in mice: contribution of opioid and excitatory amino acid receptors. Eur J Pharmacol 2008;586:179-88
   PubMed Web of Science ®Google Scholar
• Shippenberg TS, Chefer VI, Thompson AC. Delta-opioid receptor antagonists prevent sensitization to the conditioned rewarding effects of morphine. Biol Psychiatry 2009;65:169-74
   PubMed Web of Science ®Google Scholar
• Chefer VI, Shippenberg TS. Augmentation of morphine-induced sensitization but reduction in morphine tolerance and reward in delta-opioid receptor knockout mice. Neuropsychopharmacol 2009;34:887-98
   PubMed Web of Science ®Google Scholar
• Moron JA, Gullapalli S, Taylor C, Modulation of opiate-related signaling molecules in morphine-dependent conditioned behavior: conditioned place preference to morphine induces CREB phosphorylation. Neuropsychopharmacology 2010;35:955-66
   PubMed Web of Science ®Google Scholar
• Marinelli PW, Funk D, Harding S, Roles of opioid receptor subtypes in mediating alcohol-seeking induced by discrete cues and context. Eur J Neurosci 2009;30:671-8
   PubMed Web of Science ®Google Scholar
• Simmons D, Self DW. Role of mu- and delta-opioid receptors in the nucleus accumbens in cocaine-seeking behavior. Neuropsychopharmacology 2009;34:1946-57
   PubMed Web of Science ®Google Scholar
• Wang YJ, Tao YM, Li FY, Pharmacological characterization of ATPM [(-)-3-aminothiazolo[5,4-b]-N-cyclopropylmethylmorphinan hydrochloride], a novel mixed kappa-agonist and mu-agonist/-antagonist that attenuates morphine antinociceptive tolerance and heroin self-administration behavior. J Pharmacol Exp Ther 2009;329:306-13
   PubMed Web of Science ®Google Scholar
• Carroll FI, Harris LS, Aceto MD. Effects of JDTic, a selective kappa-opioid receptor antagonist, on the development and expression of physical dependence on morphine using a rat continuous-infusion model. Eur J Pharmacol 2005;524:89-94
   PubMed Web of Science ®Google Scholar
• Ruedi-Bettschen D, Rowlett JK, Spealman RD, Platt DM. Attenuation of cocaine-induced reinstatement of drug seeking in squirrel monkeys: kappa opioid and serotonergic mechanisms. Psychopharmacology 2010;210:169-77
   PubMed Web of Science ®Google Scholar
• Redila VA, Chavkin C. Stress-induced reinstatement of cocaine seeking is mediated by the kappa opioid system. Psychopharmacology 2008;200:59-70
   PubMed Web of Science ®Google Scholar
• Aldrich JV, Patkara KA, McLaughlinb JP. Zyklophin, a systemically active selective kappa opioid receptor peptide antagonist with short duration of action. PNAS 2009;106:18396-401
   PubMed Web of Science ®Google Scholar
• Beardsley PM, Howard JL, Shelton KL, Carroll FI. Differential effects of the novel kappa opioid receptor antagonist, JDTic, on reinstatement of cocaine-seeking induced by footshock stressors vs cocaine primes and its antidepressant-like effects in rats. Psychopharmacology 2005;183:118-26
   PubMed Web of Science ®Google Scholar
• Logrip ML, Janaka PH, Dorit R. Blockade of ethanol reward by the kappa opioid receptor agonist U50,488H. Alcohol 2009;43:359-65
   PubMed Web of Science ®Google Scholar
• Knoll AT, Meloni EG, Thomas JB, Anxiolytic-like effects of kappa-opioid receptor antagonists in models of unlearned and learned fear in rats. J Pharmacol Exp Ther 2007;323:838-45
   PubMed Web of Science ®Google Scholar
• Jackson KJ, Carroll FI, Negus SS, Damaj MI. Effect of the selective kappa-opioid receptor antagonist JDTic on nicotine antinociception, reward, and withdrawal in the mouse. Psychopharmacology 2010;210:285-9
   PubMed Web of Science ®Google Scholar
• Sakoori K, Murphy NP. Expression of morphine-conditioned place preference is more vulnerable than naloxone-conditioned place aversion to disruption by nociceptin in mice. Neurosci Lett 2008;443:108-12
   PubMed Web of Science ®Google Scholar
• Shoblock JR, Wichmann J, Maidment NT. The effect of a systemically active ORL-1 agonist, Ro 64-6198, on the acquisition, expression, extinction, and reinstatement of morphine conditioned place preference. Neuropharmacology 2005;49:439-46
   PubMed Web of Science ®Google Scholar
• Economidou D, Hansson AC, Weiss F, Dysregulation of nociceptin/orphanin FQ activity in the amygdala is linked to excessive alcohol drinking in the rat. Biol Psychiatry 2008;64:211-18
   PubMed Web of Science ®Google Scholar
• Toll L, Khroyan TV, Polgar WE, Comparison of the antinociceptive and antirewarding profiles of novel bifunctional nociceptin receptor/mu-opioid receptor ligands: implications for therapeutic applications. J Pharmacol Exp Ther 2009;331:954-64
   PubMed Web of Science ®Google Scholar
• LaLumiere RT, Kalivas PW. Glutamate release in the nucleus accumbens core is necessary for heroin seeking. J Neurosci 2008;28:3170-7
   PubMed Web of Science ®Google Scholar
• Manzanedo C, Aguilar MA, Rodriguez-Arias M, Minarro J. Effects of dopamine antagonists with different receptor blockade profiles on morphine-induced place preference in male mice. Behav Brain Res 2001a;121:189-97
   PubMed Web of Science ®Google Scholar
• Manzanedo C, Serrano A, Aguilar MA, Effects of CGS 10746B on hyperactivity and place preference induced by morphine. Behav Brain Res 2001b;126:23-32
   PubMed Web of Science ®Google Scholar
• Rodriguez-Arias M, Pinazo J, Minarro J, Stinus L. Effects of SCH 23390, raclopride, and haloperidol on morphine withdrawal-induced aggression in male mice. Pharmacol Biochem Behav 1999;64:123-30
   PubMed Web of Science ®Google Scholar
• Rodriguez-Arias M, Aguilar MA, Minarro J. The dopamine release inhibitor CGS 10746B blocks conditioned physical signs of morphine withdrawal. Addict Biol 2003;8:167-72
   PubMed Web of Science ®Google Scholar
• He X, Xiao L, Sui N. Effects of SCH23390 and spiperone administered into medial striatum and intermediate medial mesopallidum on rewarding effects of morphine in day-old chicks. Eur J Pharmacol 2010;627:165-41
   Google Scholar
• Serrano A, Manzanedo C, Aguilar MA, Effects of DA D1 and D2 antagonists on the sensitization to the motor effects on morphine in mice. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:1263-71
   PubMed Web of Science ®Google Scholar
• See RE. Dopamine D1 receptor antagonism in the prelimbic cortex blocks the reinstatement of heroin-seeking in an animal model of relapse. Int J Neuropsychopharmacol 2009;12:431-6
   PubMed Web of Science ®Google Scholar
• Tobin S, Newman AH, Quinn T, Shalev U. A role for dopamine D1-like receptors in acute food deprivation-induced reinstatement of heroin seeking in rats. Int J Neuropsychopharmacol 2009;12:217-26
   PubMed Web of Science ®Google Scholar
• McMahon LR, Li JX, Carroll FI, France CP. Some effects of dopamine transporter and receptor ligands on discriminative stimulus, physiologic, and directly observable indices of opioid withdrawal in rhesus monkeys. Psychopharmacology 2009;203:411-20
   PubMed Web of Science ®Google Scholar
• Li SX, Zou Y, Liu LJ, Aripiprazole blocks reinstatement but not expression of morphine conditioned place preference in rats. Pharmacol Biochem Behav 2009;92:370-5
   PubMed Web of Science ®Google Scholar
• Cabral A, Ruggiero RN, Nobre MJ, GABA and opioid mechanisms of the central amygdala underlie the withdrawal-potentiated startle from acute morphine. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:334-44
   PubMed Web of Science ®Google Scholar
• Yoon SS, Kim JA, Lee BH, Role for GABA agonists in the nucleus accumbens in regulating morphine self-administration. Neurosci Lett 2009;462:289-93
   PubMed Web of Science ®Google Scholar
• Spano MS, Fattore L, Fratta W, Fadda P. The GABAB receptor agonist baclofen prevents heroin-induced reinstatement of heroin-seeking behavior in rats. Neuropharmacology 2007;52:1555-62
   PubMed Web of Science ®Google Scholar
• Sahraei H, Etemadi L, Rostami P, GABAB receptors within the ventral tegmental area are involved in the expression and acquisition of morphine-induced place preference in morphine-sensitized rats. Pharmacol Biochem Behav 2009;91:409-16
   PubMed Web of Science ®Google Scholar
• Heinmiller A, Ting-A-Kee R, Vargas-Perez H, Tegmental pedunculopontine glutamate and GABA-B synapses mediate morphine reward. Behav Neurosci 2009;123:145-55
   PubMed Web of Science ®Google Scholar
• Heinrichs SC, Leite-Morris KA, Carey RJ, Kaplan GB. Baclofen enhances extinction of opiate conditioned place preference. Behav Brain Res 2010;207:353-9
   PubMed Web of Science ®Google Scholar
• Franklin TR, Harper D, Kampman K, The GABA B agonist baclofen reduces cigarette consumption in a preliminary double-blind placebo-controlled smoking reduction study. Drug Alcohol Depend 2009;103:30-6
   PubMed Web of Science ®Google Scholar
• Maldonado C, Rodriguez-Arias M, Aguilar MA, Minarro J. GHB ameliorates naloxone-induced conditioned place aversion and physical aspects of morphine withdrawal in mice. Psychopharmacology 2004;177:130-40
   PubMed Web of Science ®Google Scholar
• Tehrani SP, Daryaafzoon M, Bakhtiarian A, The effects of lamotrigine on the acquisition and expression of morphine-induced place preference in mice. Pak J Biol Sci 2009;12:33-9
   PubMedGoogle Scholar
• Maldonado C, Cauli O, Rodriguez-Arias M, Memantine presents different effects from MK-801 in motivational and physical signs of morphine withdrawal. Behav Brain Res 2003;144:25-35
   PubMed Web of Science ®Google Scholar
• Ribeiro Do Couto B, Aguilar MA, Manzanedo C, Effects of NMDA receptor antagonists (MK-801 and memantine) on the acquisition of morphine-induced conditioned place preference in mice. Prog Neuropsychopharmacol Biol Psychiatry 2004;28:1035-43
   PubMed Web of Science ®Google Scholar
• Ribeiro Do Couto B, Aguilar MA, Manzanedo C, NMDA glutamate but not dopamine antagonists blocks drug-induced reinstatement of morphine place preference. Brain Res Bull 2005;64:493-503
   PubMed Web of Science ®Google Scholar
• Aguilar MA, Manzanedo C, Do Couto BR, Memantine blocks sensitization to the rewarding effects of morphine. Brain Res 2009;1288:95-104
   PubMed Web of Science ®Google Scholar
• Mendez IA, Trujillo KA. NMDA receptor antagonists inhibit opiate antinociceptive tolerance and locomotor sensitization in rats. Psychopharmacology 2008;196:497-509
   PubMed Web of Science ®Google Scholar
• Comer SD, Sullivan MA. Memantine produces modest reductions in heroin-induced subjective responses in human research volunteers. Psychopharmacology 2007;193:235-45
   PubMed Web of Science ®Google Scholar
• Shabat-Simon M, Levy D, Amir A, Dissociation between rewarding and psychomotor effects of opiates: differential roles for glutamate receptors within anterior and posterior portions of the ventral tegmental area. J Neurosci 2008;28:8406-16
   PubMed Web of Science ®Google Scholar
• van der Kam EL, De Vry J, Tzschentke TM. 2-Methyl-6-(phenylethynyl)-pyridine (MPEP) potentiates ketamine and heroin reward as assessed by acquisition, extinction, and reinstatement of conditioned place preference in the rat. Eur J Pharmacol 2009a;606:94-101
   PubMed Web of Science ®Google Scholar
• van der Kam EL, De Vry J, Tzschentke TM. The mGlu5 receptor antagonist 2-methyl-6-(phenylethynyl)pyridine (MPEP) supports intravenous self-administration and induces conditioned place preference in the rat. Eur J Pharmacol 2009b;607:114-20
   PubMed Web of Science ®Google Scholar
• Rahman S, Lopez-Hernandez GY, Corrigall WA, Papke RL. Neuronal nicotinic receptors as brain targets for pharmacotherapy of drug addiction. CNS Neurol Disord Drug Targets 2008;7:422-41
   PubMed Web of Science ®Google Scholar
• Buccafusco JJ, Bain JN. A 24-h access I.V. self-administration schedule of morphine reinforcement and the estimation of recidivism: Pharmacological modification by arecoline. Neuroscience 2007;149:487-98
   PubMed Web of Science ®Google Scholar
• Esmaeili B, Basseda Z, Dehpour AR. Antagonism of muscarinic M1 receptors by dicyclomine inhibits the consolidation of morphine-associated contextual memory. Brain Res Bull 2008;76:380-7
   PubMed Web of Science ®Google Scholar
• Zhai H, Wu P, Chen S, Effects of scopolamine and ketamine on reconsolidation of morphine conditioned place preference in rats. Behav Pharmacol 2008;19:211-6
   PubMed Web of Science ®Google Scholar
• Zhou W, Liu H, Zhang F, Role of acetylcholine transmission in nucleus accumbens and ventral tegmental area in heroin-seeking induced by conditioned cues. Neuroscience 2007;144:1209-18
   PubMed Web of Science ®Google Scholar
• Lia X, Lib JX, Zhua X, Effects of physostigmine on the conditioned hyperactivity and locomotor sensitization to morphine in rats. Behav Brain Res 2010;206:223-8
   PubMed Web of Science ®Google Scholar
• Parolaro D, Rubino T. The role of the endogenous cannabinoid system in drug addiction. Drug News Perspect 2008;21:149-57
   PubMed Web of Science ®Google Scholar
• Manzanedo C, Aguilar MA, Rodriguez-Arias M, Cannabinoid agonist-induced sensitisation to morphine place preference in mice. Neuroreport 2004;15:1373-7
   PubMed Web of Science ®Google Scholar
• Caille S, Parsons LH. Cannabinoid modulation of opiate reinforcement through the ventral striatopallidal pathway. Neuropsychopharmacology 2006;31:804-13
   PubMed Web of Science ®Google Scholar
• Alvarez-Jaimes L, Polis I, Parsons LH. Attenuation of cue-induced heroin-seeking behavior by cannabinoid CB1 antagonist infusions into the nucleus accumbens core and prefrontal cortex, but not basolateral amygdala. Neuropsychopharmacology 2008;33:2483-93
   PubMed Web of Science ®Google Scholar
• Azizi P, Haghparasta A, Hassanpour-Ezatti M. Effects of CB1 receptor antagonist within the nucleus accumbens on the acquisition and expression of morphine-induced conditioned place preference in morphine-sensitized rats. Behav Brain Res 2009;197:119-24
   PubMed Web of Science ®Google Scholar
• Haghparast A, Azizi P, Hassanpour-Ezatti M, Sub-chronic administration of AM251, CB1 receptor antagonist, within the nucleus accumbens induced sensitization to morphine in the rat. Neurosci Lett 2009;467:43-7
   PubMed Web of Science ®Google Scholar
• Samini M, Kardan A, Mehr SE. Alpha-2 agonists decrease expression of morphine-induced conditioned place preference. Pharmacol Biochem Behav 2008;88:403-6
   PubMed Web of Science ®Google Scholar
• Gish EC, Miller JL, Honey BL, Johnson PN. Lofexidine, an {alpha}2-receptor agonist for opioid detoxification. Ann Pharmacother 2010;44:343-51
   PubMed Web of Science ®Google Scholar
• Greenwell TN, Walker BM, Cottone P, The alpha1 adrenergic receptor antagonist prazosin reduces heroin self-administration in rats with extended access to heroin administration. Pharmacol Biochem Behav 2009;91:295-302
   PubMed Web of Science ®Google Scholar
• Kang L, Wang D, Li B, Mirtazapine, a noradrenergic and specific serotonergic antidepressant, attenuates morphine dependence and withdrawal in Sprague-Dawley rats. Am J Drug Alcohol Abuse 2008;34:541-52
   PubMed Web of Science ®Google Scholar
• Sofuoglu M, Sewell RA. Norepinephrine and stimulant addiction. Addict Biol 2009;14(2):119-29
   PubMed Web of Science ®Google Scholar
• Sofuoglu M. Cognitive enhancement as a pharmacotherapy target for stimulant addiction. Addiction 2010;105(1):38-48
   PubMed Web of Science ®Google Scholar
• Aston-Jones G, Smith RJ, Moorman DE, Richardson KA. Role of lateral hypothalamic orexin neurons in reward processing and addiction. Neuropharmacology 2009;56:112-21
   PubMed Web of Science ®Google Scholar
• Sharf R, Guarnieri DJ, Taylor JR, Dileone RJ. Orexin mediates morphine place preference, but not morphine-induced hyperactivity or sensitization. Brain Res 2010;1317:24-32
   PubMed Web of Science ®Google Scholar
• Shalev U, Erb S, Shaham Y. Role of CRF and other neuropeptides in stress-induced reinstatement of drug seeking. Brain Res 2010;1314:15-28
   PubMed Web of Science ®Google Scholar
• Zhou Y, Leri F, Cummins E, Involvement of arginine vasopressin and V1b receptor in heroin withdrawal and heroin seeking precipitated by stress and by heroin. Neuropsychopharmacology 2008;33:226-36
   PubMed Web of Science ®Google Scholar
• Valjent E, Corbille AG, Bertran-Gonzalez J, Inhibition of ERK pathway or protein synthesis during reexposure to drugs of abuse erases previously learned place preference. Proc Natl Acad Sci USA 2006;103:2932-7
   PubMed Web of Science ®Google Scholar
• Li YQ, Li FQ, Wang XY, Central amygdala extracellular signal-regulated kinase signaling pathway is critical to incubation of opiate craving. J Neurosci 2008;28:13248-57
   PubMed Web of Science ®Google Scholar
• Tian Y, Lee K, You I, 7-Nitroindazole, Nitric oxide synthase inhibitor, attenuates physical dependence on Butorphanol in rat. Synapse 2008;62:582-9
   PubMed Web of Science ®Google Scholar
• Manzanedo C, Aguilar MA, Do Couto BR, Involvement of nitric oxide synthesis in sensitization to the rewarding effects of morphine. Neurosci Lett 2009;464:67-70
   PubMed Web of Science ®Google Scholar
• Su RB, Wang WP, Lu XQ, Agmatine blocks acquisition and re-acquisition of intravenous morphine self-administration in rats. Pharmacol Biochem Behav 2009;92(4):676-82
   PubMed Web of Science ®Google Scholar
• Wei XL, Su RB, Wu N, Agmatine inhibits morphine-induced locomotion sensitization and morphine-induced changes in striatal dopamine and metabolites in rats. Eur Neuropsychopharmacol 2007;17(12):790-9
   PubMed Web of Science ®Google Scholar
• Haile CN, Kosten TA, Kosten TR. Pharmacogenetic treatments for drug addiction: alcohol and opiates. Am J Drug Alcohol Abuse 2008;34:355-81
   PubMed Web of Science ®Google Scholar
• Levran O, O'Hara K, Peles E, ABCB1 (MDR1) genetic variants are associated with methadone doses required for effective treatment of heroin dependence. Hum Mol Genet 2008;17:2219-27
   PubMed Web of Science ®Google Scholar
• Oslin DW, Berrettini W, Kranzler HR, A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 2003;28:1546-52
   PubMed Web of Science ®Google Scholar
• Anton RF, Oroszi G, O'Malley S, An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch Gen Psychiatry 2008;65:135-44
   PubMed Web of Science ®Google Scholar
• Nutt D, Lingford-Hughes A. Addiction: the clinical interface. Br J Pharmacol 2008;154:397-405
   PubMed Web of Science ®Google Scholar
• Martinotti G, Di Nicola M, Di Giannantonio M, Janiri L. Aripiprazole in the treatment of patients with alcohol dependence: a double-blind, comparison trial vs naltrexone. J Psychopharmacol 2009;23(2):123-9
   PubMed Web of Science ®Google Scholar
• Anton RF, Kranzler H, Breder C, A randomized, multicenter, double-blind, placebo-controlled study of the efficacy and safety of aripiprazole for the treatment of alcohol dependence. J Clin Psychopharmacol 2008;28(1):5-12
   PubMed Web of Science ®Google Scholar
• Kranzler HR, Covault J, Pierucci-Lagha A, Effects of aripiprazole on subjective and physiological responses to alcohol. Alcohol Clin Exp Res 2008;32(4):573-9
   PubMed Web of Science ®Google Scholar
• Liu Y, Sun HQ, Bao YP, Subjective, cognitive/psychomotor, and physiological effects of aripiprazole in Chinese light and heavy smokers. Drug Alcohol Depend 2009;101(1-2):42-52
   PubMed Web of Science ®Google Scholar
• Karila L, Gorelick D, Weinstein A, New treatments for cocaine dependence: a focused review. Int J Neuropsychopharmacol 2008;11(3):425-38
   PubMed Web of Science ®Google Scholar
• Newton TF, Reid MS, De La Garza R, Evaluation of subjective effects of aripiprazole and methamphetamine in methamphetamine-dependent volunteers. Int J Neuropsychopharmacol 2008;11(8):1037-45
   PubMed Web of Science ®Google Scholar
• Hyman SE, Malenka RC, Nestler EJ. Neural mechanisms of addiction: the role of reward-related learning and memory. Annu Rev Neurosci 2006;29:565-98
   PubMed Web of Science ®Google Scholar